What is IBO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IBO?

P/E (TTM) is 38.98 and 52-week range is $2.43 to $10.47 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IBO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IBO?

The company profile lists revenue (TTM) near $3K, net income (TTM) near $58K, EPS (TTM) near -$0.09 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Impact Biomedical Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Houston, Texas, US, 8.5M shares outstanding, ISIN US45259L3042 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Impact Biomedical Inc

$IBO

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Impact Biomedical Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.

Employees

Website

www.impactbiomedinc.com/

IPO

2024-09-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE MKT LLC

ISIN

US45259L3042

Headquarters

Houston, Texas, US

Shares outstanding

8.5M

NAICS sector

Manufacturing

Institutional ownership

3.56%

Browse other companiesFree AI scores and summaries for more stocks